A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

Por Andersen, P S, Stryhn, A, Hansen, B E, Fugger, L, Engberg, J, Buus, S
Publicado em 1996

Improved recovery of group A beta-hemolytic streptococci with a new selective medium.

Por Carlson, J R, Merz, W G, Hansen, B E, Ruth, S, Moore, D G
Publicado em 1985

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy

Por Flink, H J, Sprengers, D, Hansen, B E, van Zonneveld, M, de Man, R A, Schalm, S W, Janssen, H L A
Publicado em 2005

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy

Por Veldt, B J, Saracco, G, Boyer, N, Cammà, C, Bellobuono, A, Hopf, U, Castillo, I, Weiland, O, Nevens, F, Hansen, B E, Schalm, S W
Publicado em 2004

Epidemiological trends of pre‐malignant gastric lesions: a long‐term nationwide study in the Netherlands

Por de Vries, A C, Meijer, G A, Looman, C W N, Casparie, M K, Hansen, B E, van Grieken, N C T, Kuipers, E J
Publicado em 2007

Authors' reply

Por van Dieren, J M, van Vuuren, A J, Kuipers, E J, Hansen, B E, Kusters, J G, Nieuwenhuis, E E S, van der Woude, C J
Publicado em 2006

Relapse after treatment with peginterferon α‐2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B

Por Flink, H J, Buster, E H C J, Merican, I, Nevens, F, Kitis, G, Cianciara, J, de Vries, R A, Hansen, B E, Schalm, S W, Janssen, H L A
Publicado em 2007

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotr...

Por van Nunen, A B, Hansen, B E, Suh, D J, Löhr, H F, Chemello, L, Fontaine, H, Heathcote, J, Song, B C, Janssen, H L A, de Man, R A, Schalm, S W
Publicado em 2003